GlassScriptPhysician profile
Ayesha Z Butt
NPI 1164669651
$3,687.34
in general payments reported to CMS, 2019-2025
34 companies · $795 in 2025
The $795 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $74.26 · 2021: $351 · 2022: $403 · 2023: $558 · 2024: $784 · 2025: $795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,136.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $391.14 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $390.37 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $375.45 | 2019-2025 | |
| Lilly USA, LLC | $351.78 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $275.38 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $217.00 | 2019-2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $207.99 | 2021-2025 | |
| Abbvie INC. | $206.31 | 2021-2024 | Vraylar, Synthroid, Ubrelvy |
| Merck Sharp & Dohme LLC | $171.86 | 2019-2025 | Capvaxive, Vaxelis, Gardasil 9 |
| Exact Sciences Corporation | $126.99 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $117.60 | 2019-2024 | Veozah |
| Amgen INC. | $108.81 | 2023-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.26 | 2019-2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $74.06 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $70.20 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $59.32 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.72 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $44.07 | 2019 | |
| Vanda Pharmaceuticals INC. | $39.85 | 2021-2022 | |
| Dynavax Technologies Corporation | $38.35 | 2021-2024 | Heplisav-B |
| Dexcom, INC. | $37.58 | 2025 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $33.38 | 2024 | Sapien 3 Ultra Resilia |
| Scilex Pharmaceuticals INC. | $27.59 | 2019 | |
| Alkermes, INC. | $24.15 | 2022 | |
| Alexion Pharmaceuticals, INC. | $22.77 | 2025 | Koselugo |
| Novartis Pharmaceuticals Corporation | $20.07 | 2025 | |
| Gilead Sciences, INC. | $18.18 | 2019 | |
| Metacel Pharmaceuticals LLC | $16.25 | 2023 | Ozobax |
| Mannkind Corporation | $16.15 | 2019 | |
| Ironshore Pharmaceuticals INC. | $15.42 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $14.43 | 2023 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $13.00 | 2022 | |
| Phadia US INC. | $12.39 | 2022 | |
| Allergan, INC. | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayesha Butt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.